This announcement is a separate document:
君实生物自愿披露关于特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理的公告
Junshi Biosciences voluntarily disclosed an announcement regarding the acceptance of the market application for the new indication of combination therapy of Toripalimab and Bevacizumab for first-line treatment of advanced liver cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated